Browse News

Found 19,732 articles

• Review of the NLRP3 Inflammasome Inhibitor RRx-001 Published in the Prestigious Scientific Journal, Drugs

  3/21/2023

  EpicentRx Inc. ("EpicentRx"), a clinical stage biopharmaceutical company, announced today the publication of a review article on its small molecule, RRx-001, a direct NLRP3 inflammasome inhibitor with activity in cancer, neurodegenerative diseases and other inflammatory conditions.

• Vaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

  3/21/2023

  Vaccinex, Inc. today announced the initiation of a single-arm open label, Phase Ib/2 study to evaluate pepinemab in combination with avelumab as second line combination immunotherapy for patients with metastatic pancreatic adenocarcinoma (PDAC), NCT05102721.

• Marvel Commences Final Study Required Prior to Initiating Human Trials

  3/21/2023

  Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has initiated the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging dog studies for its lead drug candidate MB-204.

• Cerevel Therapeutics to Present at the Stifel 2023 CNS Days

  3/21/2023

  Cerevel Therapeutics today announced that chairperson and chief executive officer Tony Coles, M.D., will participate in a fireside chat at the Stifel Virtual 2023 CNS Days on Wednesday, March 29, 2023 at 10:30 am ET.

• Inhibikase Therapeutics to Present at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders

  3/21/2023

  Inhibikase Therapeutics, Inc. today announced that Milton Werner will present at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD™), being held in Gothenburg, Sweden, and virtually, from March 28-April 1, 2023.

• Cerevance Announces Presentations at Two Medicinal Chemistry Conferences

  3/21/2023

  Cerevance today announced plans to present at two upcoming medicinal chemistry conferences.

• 

  Novartis, Biogen Scrap Gene Regulation Partnerships with Sangamo

  3/20/2023

  Sangamo Therapeutics lost two powerhouse partners Friday after it reported that both Novartis and Biogen discontinued focusing on gene regulation therapies in the neurology space.

• IGC Announces Rebranding, Changes Name to IGC Pharma, Inc.

  3/20/2023

  India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announces it will begin operating under the new name IGC Pharma, Inc., (dba IGC) effective March 30, 2023, as part of a rebranding strategy that better reflects IGC Pharma’s strategic focus and vision for the future.

• Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia

  3/20/2023

  Vaxxinity, Inc. today announced that the first subjects have been dosed in a randomized, double-blind, placebo-controlled Phase 1 clinical trial of VXX-401.

• Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia

  3/20/2023

  Karuna Therapeutics, Inc. announced positive topline results from its Phase 3 EMERGENT-3 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT in adults with schizophrenia.

• New data by AKL Therapeutics suggests investigational oral osteoarthritis drug APPA may have a promising senotherapeutic effect with potential in other diseases of ageing

  3/20/2023

  New data* presented at the 2023 Osteoarthritis Research Society International World Congress in Denver, Colorado suggest that AKL Therapeutics' investigational oral osteoarthritis drug APPA** may have a dual effect on senescence.

• Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2022 Financial Results on March 27, 2023

  3/20/2023

  Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report fourth quarter and year-end 2022 financial results on Monday, March 27, 2023.

• AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline

  3/20/2023

  AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that ten presentations will be delivered at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PDTM 2023), taking place in Gothenburg, Sweden, and virtually, on March 28 – April 1, 2023.

• Altoida Announces Upcoming Poster Presentations at AD/PD 2023

  3/20/2023

  Altoida, Inc. today announced two poster presentations at the upcoming AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, on March 28–April 1, 2023 in Gothenburg, Sweden.

• Cleveland Clinic and IBM Unveil First Quantum Computer Dedicated to Healthcare Research

  3/20/2023

  Today, Cleveland Clinic and IBM (NYSE: IBM) officially unveiled the first deployment of an onsite private sector IBM-managed quantum computer in the United States.

• Cerevance Announces Presentations at AD/PD™ 2023 International Conference

  3/20/2023

  Cerevance today announced plans to present two symposium oral presentations and a poster presentation at the upcoming AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, taking place in Gothenburg, Sweden, March 28 – April 1, 2023.

• Eisai Publishes Societal Value of Lecanemab Using Phase 3 Clarity Ad Data in Peer-reviewed Neurology and Therapy Journal

  3/19/2023

  Eisai Co., Ltd. announced the publication of updated results from an evaluation estimating the societal value of anti-amyloid-beta protofibril* antibody lecanemab in people living with mild cognitive impairment due to Alzheimer's disease and mild AD using data from the Phase 3 clinical study, Clarity AD by applying a validated disease simulation model.

• IRLAB to Hold Four Presentations at Scientific Congress AD/PD(TM) 2023

  3/17/2023

  IRLAB Therapeutics AB announced that it will present new data in an oral presentation and hold three poster presentations at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, AD/PD ™ 2023, held on March 28- April 1, 2023, in Gothenburg, Sweden.

• Alzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update

  3/16/2023

  Alzamend Neuro, Inc. today announced financial results for the third quarter ended January 31, 2023 and provided an update on its clinical operations.

• AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update

  3/16/2023

  AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update.